pyrazines has been researched along with tipifarnib in 6 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 4 (66.67) | 29.6817 |
| 2010's | 2 (33.33) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Alsina, M; Beaupre, DM; Buzzeo, R; Dalton, WS; Enkemann, S; Lichtenheld, MG; Nimmanapalli, R | 1 |
| Beaupre, DM; Boulware, D; Buzzeo, RW; Colaco, NM; Dalton, WS; Parquet, NA; Perez, LE; Wright, G; Yanamandra, N | 1 |
| Armand, JP; Burnett, AK; Drach, J; Harousseau, JL; Löwenberg, B; San Miguel, J | 1 |
| Boise, LH; Chen, J; David, E; Flowers, CR; Kaufman, JL; Lonial, S; Marcus, AI; Schafer-Hales, K; Sun, SY; Torre, C | 1 |
| Blaskovich, MA; Burton, M; Cubitt, C; Duong, VH; Lancet, JE; Sebti, S; Stuart, RK; Sullivan, DM; Winton, EF; Wright, JJ; Zhang, S | 1 |
1 review(s) available for pyrazines and tipifarnib
| Article | Year |
|---|---|
The emerging role of targeted therapy for hematologic malignancies: update on bortezomib and tipifarnib.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Hematologic Neoplasms; Humans; Pyrazines; Quinolones | 2007 |
1 trial(s) available for pyrazines and tipifarnib
| Article | Year |
|---|---|
A phase I clinical-pharmacodynamic study of the farnesyltransferase inhibitor tipifarnib in combination with the proteasome inhibitor bortezomib in advanced acute leukemias.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Chymotrypsin; Farnesyltranstransferase; Female; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Acute; Leukocytes, Mononuclear; Male; Maximum Tolerated Dose; Middle Aged; NF-kappa B; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Proteasome Inhibitors; Pyrazines; Quinolones | 2011 |
4 other study(ies) available for pyrazines and tipifarnib
| Article | Year |
|---|---|
Characterization of a R115777-resistant human multiple myeloma cell line with cross-resistance to PS-341.
Topics: Boronic Acids; Bortezomib; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Cell Survival; Dose-Response Relationship, Drug; Doxorubicin; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Etoposide; Farnesyltranstransferase; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Heat-Shock Proteins; Humans; Melphalan; Multiple Myeloma; Oligonucleotide Array Sequence Analysis; Phenotype; Protease Inhibitors; Protein Prenylation; Pyrazines; Quinolones; ras Proteins; Staurosporine; Tunicamycin | 2005 |
Tipifarnib and bortezomib are synergistic and overcome cell adhesion-mediated drug resistance in multiple myeloma and acute myeloid leukemia.
Topics: Antineoplastic Agents; Bone Marrow; Boronic Acids; Bortezomib; Cell Adhesion; Drug Resistance, Neoplasm; Drug Synergism; Drug Therapy, Combination; Fibronectins; Humans; Leukemia, Myeloid, Acute; Multiple Myeloma; Pyrazines; Quinolones; Stromal Cells; Tumor Cells, Cultured | 2006 |
48th annual meeting of the American Society of Hematology December 9-12, 2006, Orlando, FL.
Topics: Administration, Oral; Animals; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Disease Progression; Drug Therapy, Combination; Hematologic Diseases; Hematology; Humans; Lenalidomide; Lymphoma, B-Cell; Lymphoma, Large B-Cell, Diffuse; Melphalan; Multiple Myeloma; Prednisone; Pyrazines; Quinolones; Recurrence; Stem Cell Transplantation; Thalidomide; Transplantation Conditioning; Transplantation, Autologous | 2007 |
Tipifarnib sensitizes cells to proteasome inhibition by blocking degradation of bortezomib-induced aggresomes.
Topics: Apoptosis; Autophagy; Boronic Acids; Bortezomib; Cell Line, Tumor; Drug Synergism; Drug Therapy, Combination; Humans; Multiple Myeloma; Proteasome Inhibitors; Pyrazines; Quinolones; Ubiquitination | 2010 |